Container closure integrity, and the tests that actually probe it
A sterile product is sterile only for as long as its container closure system excludes the outside world. Integrity is testable, and the tests are cheap by the standards of…
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Bioburden
Three compendial method families are in routine use and a fourth, based on a recombinant enzyme rather than crab lysate, is now compendial in its own right.
Two paragraphs setting out what this article does not allege were added at the request of the standards desk after the first version was read by two correspondents as an accusation against named companies. No company named here has been shown to us to have misrepresented a test result.
Bacterial endotoxin is the single most under-discussed contaminant in this market, and the reason is that it does not behave like the contaminants people intuitively worry about. It is not alive. It is a lipopolysaccharide fragment of the outer membrane of Gram-negative bacteria, released in quantity when those bacteria die. It is thermostable enough to survive an autoclave cycle comfortably, small enough to pass a 0.22 micron sterilising filter without hindrance, and pyrogenic in the low nanogram range. A preparation can be perfectly sterile — no viable organism anywhere in the container — and carry an endotoxin burden well above any defensible parenteral limit.
Endotoxin is a structural component of the outer membrane of Gram-negative bacteria: a lipopolysaccharide with a lipid A anchor that is the pyrogenic moiety, a core oligosaccharide, and a variable O-antigen chain. It is shed during growth and released in quantity on cell lysis, which means that killing a bacterial population does not remove its endotoxin and may increase the free concentration.
Three physical properties make it a separate discipline. It is thermally robust, surviving autoclave conditions with little loss of pyrogenicity, so terminal sterilisation is not a depyrogenation step. It is small and amphipathic, forming aggregates that pass a 0.22 micron membrane without difficulty, so sterilising filtration is not a depyrogenation step either. And it is active in humans at very low mass — the threshold pyrogenic dose corresponds to something in the region of a nanogram per kilogram of body weight.
The practical consequence is stark. A vial can pass a sterility test, contain no viable organism of any kind, and carry an endotoxin burden many times a defensible parenteral limit, because the organisms responsible died somewhere upstream in a water system, a holding tank or a poorly stored component.1
The gel-clot method is the oldest and simplest: lysate is combined with the sample, incubated, and the tube inverted. A firm clot that does not slip is a positive. It is a limit test, and by testing serial dilutions it becomes semi-quantitative. Its virtues are robustness and independence from instrumentation; its limitation is resolution.
Turbidimetric methods read the increasing turbidity produced by clotting protein formation, either as an endpoint at fixed time or kinetically as the time to reach a defined turbidity. Chromogenic methods substitute a synthetic peptide substrate that releases a chromophore when cleaved by the activated enzyme, and read absorbance. The kinetic chromogenic variant — measuring the time to a defined absorbance change against a standard curve — is the method of record for most modern release testing, offering quantitation across several orders of magnitude from a small sample volume.
All three are compendial, all three require a demonstration that the sample matrix neither inhibits nor enhances the reaction, and all three are calibrated against an international reference endotoxin rather than against a mass. A result reported without the method and without the inhibition-enhancement result is, once again, a number without a procedure.2
Killing the bacteria does not remove the endotoxin, and may increase the free concentration.
The limit is derived, not looked up. For a parenteral product other than an intrathecal one, the threshold pyrogenic dose is taken as five endotoxin units per kilogram of body weight per hour. The endotoxin limit for the product is that figure divided by the maximum dose per kilogram administered within an hour. For an intrathecal route the threshold falls to 0.2 endotoxin units per kilogram, a twenty-five-fold reduction that reflects the absence of the systemic buffering the bloodstream provides.
Work it for a concrete case. A seventy-kilogram subject has an hourly allowance of three hundred and fifty endotoxin units. A vial nominally containing five milligrams of peptide, reconstituted to two millilitres, from which a fifth of a millilitre is drawn, delivers a tenth of the vial contents. If the whole vial carried three hundred and fifty endotoxin units, that draw would deliver thirty-five — a tenth of the allowance. The limit expressed per milligram of peptide is what a certificate should carry, because it is the only form of the number that survives a change in reconstitution volume.
None of the arithmetic is difficult. What is missing from this trade is not the calculation but the measured numerator.3
| Vial | Label | Result (EU/vial) | EU per mg peptide | Against 350 EU/h allowance |
|---|---|---|---|---|
| 1 | 5 mg | <0.5 | <0.10 | Below quantitation |
| 2 | 5 mg | 1.2 | 0.24 | 0.3% |
| 3 | 10 mg | 2.8 | 0.28 | 0.8% |
| 4 | 5 mg | <0.5 | <0.10 | Below quantitation |
| 5 | 5 mg | 14.6 | 2.92 | 4.2% |
| 6 | 10 mg | 3.1 | 0.31 | 0.9% |
| 7 | 15 mg | 6.4 | 0.43 | 1.8% |
| 8 | 5 mg | 38.2 | 7.64 | 10.9% |
| 9 | 5 mg | 0.9 | 0.18 | 0.3% |
| 10 | 10 mg | 4.7 | 0.47 | 1.3% |
| 11 | 5 mg | <0.5 | <0.10 | Below quantitation |
| 12 | 5 mg | 112.0 | 22.40 | 32.0% |
| Single determinations by kinetic chromogenic assay at one accredited contract laboratory; method suitability established for each matrix; results expressed per vial as received and per mg of labelled nominal mass. The final column expresses the whole vial against the hourly allowance for a 70 kg subject and is arithmetic, not a safety assessment. Twelve vials from nine suppliers is not a survey. | ||||
The most uncomfortable finding in endotoxin testing over the past fifteen years is that certain formulation matrices cause added endotoxin to become undetectable over time. Spike a known quantity of reference endotoxin into a solution containing a non-ionic surfactant and a chelating buffer, hold it, and the recoverable endotoxin declines — sometimes to a small fraction of what was added — while nothing has been removed. The lipopolysaccharide aggregate state has changed, and the assay cannot see what it cannot bind.
The phenomenon is called low endotoxin recovery, and it matters because the combination of polysorbate with citrate or phosphate is extremely common in peptide and protein formulations. A hold-time study — spiking the actual product matrix and measuring recovery across the intended sample storage interval — is the standard mitigation, and it is now expected as part of method suitability for products in that formulation space.
The implication for a reader is narrow but worth stating. A negative endotoxin result on a surfactant-containing formulation, reported without a hold-time recovery study, is weaker evidence than it appears. A negative result on a reconstituted lyophilised peptide in plain water for injection, tested promptly, is considerably stronger.4
Between the second and fourth quarters the Journal purchased fourteen vials of lyophilised research peptide from nine suppliers, at catalogue prices, through ordinary channels and without identifying ourselves. Each was photographed sealed, logged, and stored at two to eight degrees on arrival. Twelve were submitted to a contract laboratory accredited to the general competence standard for testing laboratories for bacterial endotoxin determination by kinetic chromogenic assay, with method suitability established for each matrix. Two were submitted for a compendial sterility test by membrane filtration, which destroyed both.
We disclose the following limitations without being asked. Fourteen vials from nine suppliers is not a survey. Single determinations carry the uncertainty of single determinations. A negative sterility result on one vial says nothing about the batch it came from, for exactly the statistical reasons set out above. And a vial that has crossed a border in a padded envelope has a thermal and mechanical history we cannot reconstruct.
What the exercise establishes is narrower than a survey and, we think, worth publishing: that the tests exist, that they are commercially available to a private purchaser at a known price, that the numbers they return are interpretable against a calculable limit, and that nothing prevented any of the nine suppliers from commissioning them first.5
We will keep asking the five questions, printing the answers, and recording the refusals as refusals. Two companies changed their certificates after the first round of this correspondence, which is a small result for a year of letters and rather better than none. Documents to letters@compoundjournal.com; disputes about anything above to standards@compoundjournal.com.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
A quibble about depyrogenation. You imply an operation describing autoclaving alone has skipped a step, but depyrogenation of glass is only necessary if the incoming glass carries endotoxin. Vials supplied ready-to-use from a component manufacturer arrive already depyrogenated and certified as such.
— W. Stroud, Chattanooga, TN
Correct, and the text now says so. A ready-to-use component with a certificate stating its endotoxin limit is a perfectly good answer to the question; what is not an answer is autoclaving ordinary glass and describing the result as pyrogen-free.
The statistics section is the part of this I will be sending to people. I had assumed a passed sterility test meant something about the batch. It had not occurred to me that a batch with one contaminated vial in a hundred passes four times out of five.
— R. Devaney, Ballarat, VIC
A sterile product is sterile only for as long as its container closure system excludes the outside world. Integrity is testable, and the tests are cheap by the standards of…
None of what this piece asks for is commercially sensitive, and all of it is already known to whoever released the batch.
A 4 mm needle at ninety degrees without a skin pinch is adequate for essentially all adults. The persistence of 12.7 mm needles in this market is habit, not reasoning.
Reported from the analysis, not from a warning notice.
The supplier has not disputed the finding. It has not explained the gap either.
The supplier has not disputed the finding. It has not explained the gap either.